Stay updated on PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial page.

Latest updates to the PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedScreenshots show the Study Details page content and layout largely unchanged; there are no updates to core data such as status, enrollment, locations, or eligibility. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check18 days agoNo Change Detected
- Check40 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference3%

- Check47 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

- Check61 days agoChange DetectedThe page now shows Revision: v3.0.2 (replacing v3.0.1), and the Back to Top element has been removed.SummaryDifference0.2%

- Check68 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.SummaryDifference0.2%

- Check75 days agoChange DetectedThe web page has undergone significant updates, including the addition of specific facility names and locations, as well as the introduction of new drug names. Notably, the revision number has changed from v2.16.12 to v3.0.0.SummaryDifference3%

Stay in the know with updates to PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial page.